Radiance Research AcademyInternational Journal of Current Research and Review2231-21960975-5241EnglishN2026June15Healthcare Formulation, Optimization, and Evaluation of Liposomal Amphotericin B for Improved Antifungal Therapy     English0107Priti GuptaEnglish Manali RaiEnglish Saket Singh ChandelEnglishhttps://doi.org/10.31782/IJCRR.2026.181101 Background: Amphotericin B (AmB) remains a first-line therapeutic agent due to its broad-spectrum fungicidal activity and low microbial resistance. However, conventional formulations are severely restricted by dose-limiting nephrotoxicity driven by drug self-aggregation. Nanotechnology-driven drug delivery systems, particularly liposomes (L), have been widely adopted to over come these biopharmaceutical constraints. Objectives: This research aimed to formulate and optimize L-AmB using the thin-film hydration method to enhance drug stabil ity and reduce systemic toxicity, achieving high entrapment efficiency and controlled release through precise lipid-to-drug ratio modulation. Methods: L-AmB was prepared using HSPC, DSPG, and cholesterol via thin-film hydration. Preformulation studies included organoleptic evaluation, solubility analysis, melting point determination, and drug-excipient compatibility via FT-IR and DSC. The optimized formulation was characterized through standard methods. Results: The optimized formulation (Batch F4) exhibited a mean particle size of 82.4 ± 2.1 nm with a PDI of 0.142 and zeta potential of -32.5 ± 1.2 mV, indicating excellent physical stability. Entrapment efficiency reached 94.2 ± 1.5% with 92.8% yield. In vitro release studies demonstrated a sustained profile following the Higuchi model, with only 22% drug released in the first 8 hours. Stability studies confirmed refrigeration (4°C) as optimal for maintaining liposomal integrity. Conclusions: The optimized L-AmB formulation represents a safer alternative to conventional deoxycholate treatments. The sub-micron size ensures long-term stability and enhanced circulation via EPR effect. The sustained release profile minimizes the “burst effect” associated with nephrotoxicity. This study demonstrates that L-AmB offers a promising platform for improved clinical outcomes in systemic fungal infections. EnglishLiposomes, Amphotericin B, Invasive Fungal Infections, Drug Delivery Systems, Nephrotoxicity, Nanocarriers, Thin-Film Hydration.http://ijcrr.com/abstract.php?article_id=4911http://ijcrr.com/article_html.php?did=4911 1. Atole AS, Barge VU. A review on liposomes: a promising technique for drug delivery system. Int J Sci Res Sci Technol. 2023;10(3):439-461. 2. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, et al. Liposome: classification, preparation, and applications. Nanoscale Res Lett. 2013;8(1):102. 3. Bulbake U, Doppalapudi S, Kommineni N, Khan W. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12. 4. Stone NR, Bicanic T, Salim R, Hope W. Liposomal ampho tericin B (AmBisome®): A review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485-500. 5. Maertens J, Birne R, Felton T, Neofytos D, Hoenigl M. Li posomal amphotericin B and renal safety: review of the evi dence and clinical considerations. J Antimicrob Chemother. 2026;81(2):dkaf473. 6. Szoka F Jr, Papahadjopoulos D. Comparative properties and methods of preparation of lipid vesicles (liposomes). Annu Rev Biophys Bioeng. 1980;9:467-508. 7. Bangham AD, Horne RW. Negative staining of phospholipids and their structural modification by surface-active agents as ob served in the electron microscope. J Mol Biol. 1964;8(5):660 668. 8. Has C, Sunthar P. A comprehensive review on recent preparation techniques of liposomes. J Liposome Res. 2020;30(4):336-365. 9. Zhang H. Thin-film hydration followed by extrusion method for liposome preparation. Methods Mol Biol. 2023;2567:1-10. 10. Adler-Moore J, Proffitt RT. Development, characterization, effi cacy and mode of action of AmBisome, a unilamellar liposomal formulation of amphotericin B. J Liposome Res. 1993;3(3):429 450. 11. Boswell GW, Bekersky I, Buell D, Hiles R, Walsh TJ. Toxico logical profile and pharmacokinetics of a unilamellar liposomal preparation of amphotericin B (AmBisome) in rats. Antimicrob Agents Chemother. 1998;42(10):2568-2573. 12. Walsh TJ, Finberg RW, Arndt C. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutrope nia. N Engl J Med. 1999;340(10):764-771. 13. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal am photericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs. 2009;69(3):361-392. 14. Groll AH, Rijnders BJA, Walsh TJ. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal ampho tericin B. Clin Infect Dis. 2019;68(Suppl 4):S260-S274. 15. Adler-Moore J, Lewis RE, Brüggemann RJM. Preclinical safe ty, tolerability, pharmacokinetics, pharmacodynamics, and an tifungal activity of liposomal amphotericin B. Clin Infect Dis. 2019;68(Suppl 4):S244-S259.